IPS Cell Therapy » Molecular Genetics

New Governance Structure Approved by AMP Membership

Jegebliseen — Mon, 06 Feb 2012 19:55:46 +0000

Newswise — BETHESDA, MD, February 6, 2012 – The members of the Association for Molecular Pathology voted in favor of adopting significant changes to the structure of its governing body. The changes resulted in two primary refinements; 1) a shift from management by a Council to management by a Board of Directors and an Executive Committee, and 2) the transition of Subdivision Chairs from the role of Annual Meeting programming to one that focuses directly on the interests and needs of the subdivision discipline.

The shift from the Council model to a Board and Executive Committee structure allows the Board to continually appraise the Association at a high level and to develop long-range goals, plans, and policies, thus allowing the Executive Committee to focus on operational issues including the implementation of the strategy, direction, and policies established by the Board. The overall strategy of management by a Board and Executive Committee, adopted by an increasing number of nonprofit organizations, allows for greater flexibility, adaptability, and nimbleness on the part of AMP to establish and easily modify its direction moving forward.

AMP’s membership includes four distinct subdivisions; Genetics, Hematopathology, Infectious Diseases, and Solid Tumors. Each subdivision represents a vital segment of AMP membership, reflecting the diversity, vitality, and wide range of specialties encompassed by AMP members.

“AMP has now matured as an organization and is ready to be governed differently than when it was founded,” said Iris Schrijver, MD, AMP President. “Over the course of several months, we studied many aspects of nonprofit governance, examined other organizations, and discussed how to create a model that best suits AMP. Our new governance structure will facilitate decision-making that is informed and strategic.”

The overarching catalyst for the changes to the AMP governance structure is the newly implemented strategic plan. The plan centers on five essential areas: advocacy, education, innovation and improved patient care, governance, and management. AMP’s policies, programs, resources and structure will all serve to support these elements of the strategic plan. For more information about the AMP Strategic Plan, visit www.amp.org.

ABOUT AMP:
The Association for Molecular Pathology (AMP) is an international medical professional association dedicated to the advancement, practice, and science of clinical molecular laboratory medicine and translational research based on the applications of molecular biology, genetics, and genomics. For more information, please visit http://www.amp.org/about/strategic_plan.cfm.

Comment/Share

See the original post:
New Governance Structure Approved by AMP Membership

Young stem cells make rapidly aging mice live longer and healthier – Video

Anepuctulutty — Sat, 04 Feb 2012 09:10:24 +0000

www.youtube.com/watch?v=3Ju-VzT2DwU

17-01-2012 13:20 Researchers from the University of Pittsburgh School of Medicine found that a shot of young stem cells made rapidly aging mice live longer and healthier. Johnny Huard, Ph.D., professor in the Departments of Orthopaedic Surgery and of Microbiology and Molecular Genetics, Pitt School of Medicine, and director of the Stem Cell Research Center at Pitt and Children’s Hospital of Pittsburgh of UPMC, and Laura Niedernhofer, MD, Ph.D., associate professor in the University of Pittsburgh’s Department of Microbiology and Molecular Genetics and the University of Pittsburgh Cancer Institute (UPCI), discuss their research findings, which were published in the Jan. 3 edition of Nature Communications.

See the article here:
Young stem cells make rapidly aging mice live longer and healthier – Video

Plant and Microbial Biology 160 – Lecture 1 – Video

shereePut — Thu, 02 Feb 2012 23:40:22 +0000

www.youtube.com/watch?v=0yvsgng6Bb4

18-01-2012 15:40 Plant Molecular Genetics

Read the rest here:
Plant and Microbial Biology 160 – Lecture 1 – Video

Ambry Genetics, Looking to Entice Pharma, Rolls out CHO Cell Expression Array

achurenics — Thu, 02 Feb 2012 02:20:23 +0000

Full-text access for premium subscribers only. Existing premium subscribers login here . New to GenomeWeb? Register quickly here . Sage Science is pleased to announce the introduction of the BluePippin DNA size selection system, a pulsed-field electrophoresis version of its popular Pippin Prep instrument.

See the original post here:
Ambry Genetics, Looking to Entice Pharma, Rolls out CHO Cell Expression Array

Myriad Genetics Profit Up, Lifts FY12 Outlook; Stock Up

Jegebliseen — Thu, 02 Feb 2012 02:20:22 +0000

(RTTNews.com) – Myriad Genetics Inc. (MYGN) Tuesday reported a 17 percent rise in second-quarter earnings on double-digit revenue growth at Molecular diagnostic testing segment and contribution of Companion diagnostic acquired last May. Both earnings and revenue for the quarter topped analysts estimates.

Looking ahead, the company also raised its outlook for full year 2012. Buoyed by the results, Myriad Genetics shares gained more than 5 percent in extended trade on the Nasdaq.

Net income for the second quarter rose to $28.3 million or $0.33 per share from $24.2 million or $0.26 per share in the prior year. On average, 19 analysts polled by Thomson Reuters expected earnings of $0.31 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter grew 22 percent to $123 million from $100.4 million a year ago. Analysts expected revenues of $115.29 million.

Molecular diagnostic testing revenue grew 17 percent and accounted for most of the revenues, as all segments and products saw growth. Within the segment, Oncology revenue rose 15 percent, and Women's Health revenue by 22 percent. Revenue from Companion diagnostic service was $5.2 million.

Myriad Genetics now expects 2012 earnings in a range of $1.24 to $1.28 per share and revenues of $465 million to $475 million. Analysts currently expect earnings of $1.24 per share and revenues of $461.45 million for the year.

The company had earlier forecast 2012 earnings in the range of $1.20 to $1.25 per share with revenues of $465 million to $475 million.

Salt Lake City, Utah-based Myriad Genetics is a molecular diagnostic company that focuses on the development of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the U.S.

MYGN closed Tuesday on the Nasdaq at $23.66, up $0.40 or 1.72%, on a volume of about 1.8 million shares. In after hours, the stock further gained $1.24 or 5.24%.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

See the article here:
Myriad Genetics Profit Up, Lifts FY12 Outlook; Stock Up

Molecular test more accurate in predicting lung cancer survival

jos — Sun, 29 Jan 2012 01:49:54 +0000

Home > News > health-news

Washington, Jan 27 : An available
molecular test can predict the likelihood of death from
early-stage lung cancer more accurately than conventional
methods, according to a team of scientists.

The international team, led by
scientists at the University of California, San Francisco
(UCSF), conducted the two largest clinical studies ever done on
the molecular genetics of lung cancer.

They demonstrated how the test, which measures the activity of
fourteen genes in cancerous tissue, improves the accuracy of
prognosis. This in turn could guide treatments for patients
with the most common form of the disease, non-squamous
non-small cell lung cancer.

The two independent clinical trials included one blinded study
involving the analysis of tissue samples from 433 people with
early-stage lung cancer in northern California and another
study involving 1,006 people with early-stage lung cancer in
China. In both trials, the team showed that the test could
accurately predict whether the odds of death within five years
of surgery to remove a lung cancer were low, intermediate, or
high.

?It?s quite exciting? This has the potential to help hundreds
of thousands of people every year survive longer,? said David
Jablons, MD, the Ada Distinguished Professor in Thoracic
Oncology and leader of the Thoracic Oncology Program at the
Helen Diller Family Comprehensive Cancer Center at UCSF.

Jablons co-led the study with Michael Mann, MD, a UCSF
Associate Professor of Cardiothoracic Surgery.

Today, doctors assess early-stage lung cancers by their size,
location and microscopic appearance. This information, known as
staging, is then used to guide the use of additional treatment
following surgery. If doctors could more precisely gauge
prognosis, more people who might benefit from additional
therapy could receive it immediately after surgery, before any
residual cancer has had a chance to grow.

Evidence from other studies suggests that chemotherapy given in
early-stage lung cancer helps thwart recurrence when there is
evidence of lymph node involvement. Such involvement increases
the risk of other, undetectable metastasis.

The scientists plan to design a large clinical trial that would
seek to confirm that using the algorithm to guide therapy helps
people with lung cancer survive longer.

The study conducted in China is the first major clinical trial
result to emerge from the China Clinical Trials Consortium
(CCTC), a collaboration between hospitals and universities
across mainland China that was founded with the help of leaders
from the UCSF Thoracic Oncology Program to confront the
epidemic of lung cancer in China.

?The CCTC represents a revolutionary new collaborative approach
to clinical research among Chinese and Western experts,? said
Mann.

?It is fitting that this body?s first major effort may support
a molecular personalization of lung cancer care, and yield one
of the first examples that fundamental tumour biology reaches
across ethnic lines and can be used to try to improve outcomes
for a large percentage of patients,? he said.

This study was reported in the Lancet. (ANI)

Share this article at

Yearly Horoscope of 2012 for the Zodiac
Sign:

Sagittarius
Scorpio
    Libra    Virgo    Leo
    Cancer
    Gemini
    Taurus
    Aries
    Pisces
    Aquarius
    Capricon

National Cancer Institute

AddeneibBrada — Fri, 27 Jan 2012 20:27:54 +0000

In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) has demonstrated that an available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods…

Breakthrough could aid lung cancer patients

DamEvasia — Fri, 27 Jan 2012 00:30:38 +0000

In a finding that could improve the survival odds for early-stage lung cancer patients, UCSF researchers determined a new molecular test can predict more accurately than current diagnostic methods which tumors are more…

Read the original:
Breakthrough could aid lung cancer patients

New lung cancer test predicts survival

Querirrepsy — Fri, 27 Jan 2012 00:30:37 +0000

In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco has demonstrated that an available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods.

Continue reading here:
New lung cancer test predicts survival

GeneThera Acquires Majority Stake in Applied Genetics

JekapedoAmake — Thu, 26 Jan 2012 08:50:25 +0000

Full-text access for registered users only. Existing users login here . New to GenomeWeb

Read more from the original source:
GeneThera Acquires Majority Stake in Applied Genetics

Blueprint Medicines Appoints Oncology Drug Development Leader Christoph Lengauer as Chief Scientific Officer

shereePut — Wed, 25 Jan 2012 00:37:04 +0000

Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, today announced the appointment of Christoph Lengauer, Ph.D., as chief scientific officer.

See the rest here:
Blueprint Medicines Appoints Oncology Drug Development Leader Christoph Lengauer as Chief Scientific Officer

Molecular plant signal could be drought breaker

jonaserag — Sun, 22 Jan 2012 20:05:02 +0000

SCIENTISTS have found a molecular signal in plants which may act as a drought alarm, allowing them to adapt to drought conditions.

Originally posted here:
Molecular plant signal could be drought breaker

Genetic lab at cancer centre

grandma — Thu, 19 Jan 2012 22:38:07 +0000

To bring the subject of molecular genetics on centre stage, the hospital will also organise a two-day national-level seminar on genetics ' Genomics 2012 ' in collaboration with the Union ministry of science and technology from Saturday, January 21.

See the article here:
Genetic lab at cancer centre

UAB, Baylor research may advance understanding of Lou Gehrig's disease (ALS)

buymedicationszz — Thu, 19 Jan 2012 22:38:07 +0000

The researchers have shown how a cell-to-cell signaling system between motor neurons and muscle cells functions in the worms and flies, and what happens when this signaling fails in those animals.

Originally posted here:
UAB, Baylor research may advance understanding of Lou Gehrig's disease (ALS)

Hongyu Zhao is appointed to the Hiscock Professorship

DamEvasia — Thu, 19 Jan 2012 01:55:22 +0000

Hongyu Zhao, who was designated as the Ira V. Hiscock Professor of Biostatistics in the School of Public Health, develops in his laboratory mathematical, statistical, computational, and visualization tools needed to address scientific problems in molecular biology and genetics.

Continued here:
Hongyu Zhao is appointed to the Hiscock Professorship

Careers in Genetics: Dr. Christopher Cunniff – Video

kitaGakyFax — Wed, 18 Jan 2012 19:44:01 +0000

www.youtube.com/watch?v=NlHsouDN2rk

15-09-2011 14:59 What’s it like to study genetics and be a geneticist? What are the career options, training paths, typical settings, what do medical geneticists do, what is a typical day like, the lifestyle aspects of and many rewards of this fascinating and flexible career path.

See original here:
Careers in Genetics: Dr. Christopher Cunniff – Video

Careers in Genetics: Dr. Mira Irons – Video

RextGues — Wed, 18 Jan 2012 19:44:01 +0000

www.youtube.com/watch?v=cTN0IZhrROg

15-09-2011 14:46 What’s it like to study genetics and be a geneticist?

Read more from the original source:
Careers in Genetics: Dr. Mira Irons – Video

10/27/2011 Negotiating the Academic Job Offer for Science

Nayua — Wed, 18 Jan 2012 19:44:00 +0000

www.youtube.com/watch?v=4o4yIYR9oi0

28-10-2011 08:08 On Thursday, October 27, 2011, a panel of Duke faculty members, and a postdoc who was successful on the academic job market (20 applications, 7 interviews, 3 offers), discussed the negotiation process.

See original here:
10/27/2011 Negotiating the Academic Job Offer for Science

Pamela Sklar: 2011 Allen Institute for Brain Science Symposium – Video

jonaserag — Wed, 18 Jan 2012 19:44:00 +0000

www.youtube.com/watch?v=BIEl3o8fyNw

07-10-2011 12:08 Pamela Sklar, Mount Sinai School of Medicine “Genomics and psychiatry”

FringeElements- Racism vs. Evolution, pt 2: Pretending to Be Academic – Video

de30 — Wed, 18 Jan 2012 19:43:59 +0000

www.youtube.com/watch?v=_tn75DdBN9U

05-12-2011 07:48 Expand me! Fringe’s video: www.youtube.com Part 1 of the series: www.youtube.com Fringe, this is quickly turning from a conflict of genetics vs. racism into a conflict of true education and access to knowledge vs.